|05/05/15||Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases|
|Collaboration Allows Portola to Advance Product Candidates Outside of Core Focus While Retaining Economics and Flexibility for Future Development
SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced a collaboration with Ora, Inc. for the development of Portola's highly selective Syk inhibitor, PRT2761, in ophthalmic diseases. The inhibition of Syk may more completely prevent activation of mast cells in ocular allergy and, therefore, ... |
|05/05/15||Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference|
|SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, at 10:00 a.m. Pacific Time in Las Vegas.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharma... |
|04/29/15||Portola Pharmaceuticals to Announce First Quarter 2015 Financial Results and Host Conference Call on Wednesday, May 6|
|SOUTH SAN FRANCISCO, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2015, and provide a general business overview on Wednesday, May 6, 2015, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (877) 415-3182 from the U.S. and Canada or +1(857) 244... |
|04/08/15||Portola Pharmaceuticals Announces New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint for Prolonged Reversal of Factor Xa Inhibitor Eliquis (apixaban)|
|Data Support Potential Registration of Andexanet Alfa Bolus-Only and Bolus-Plus-Continuous-Infusion Dosing Regimens to Reverse Anticoagulant Effect of Factor Xa Inhibitors
SOUTH SAN FRANCISCO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced positive topline results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study, which evaluated the safety and effi... |
|03/10/15||Portola Announces Pricing of Public Offering of Common Stock|
|SOUTH SAN FRANCISCO, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today the pricing of its underwritten public offering of 2,495,652 shares of its common stock at a price to the public of $40.00 per share. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 374,348 shares from Portola at the public offering price. The offering is expected to close on March 13, 2015, subject to customar... |